A Case Study in Regulatory Innovation: Pharmacogenomics at FDA
This article was originally published in RPM Report
Executive Summary
FDA’s idea to encourage “voluntary” submission of pharmacogenomic data started slow—but the program has paid significant dividends for the agency. In addition to building knowledge and advancing the use of PKG in drug regulation, it has also won over industry and become a case study to support broader funding of regulatory science.